Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Nuvation Bio Inc.
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
April 10, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
March 28, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
March 25, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
March 14, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
January 08, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
January 08, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Announces Departure of Chief Financial Officer
November 13, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
June 01, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 15, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
December 19, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
August 01, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
July 18, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
June 27, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
May 09, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Tickers
NUVB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.